Massmedica S.A. ($MSM) reported a solid quarter in Q3 2026, with revenue rising to $1.05 billion, up 7.8% from a year earlier. Gross profit increased to $430.4 million, while operating profit climbed 29.0% to $106.7 million, reflecting stronger profitability across the business.
Net income attributable to common shareholders advanced 41.4% year over year to $80.4 million, and diluted earnings per share rose to $1.44. The improvement suggests the company converted higher sales into bottom-line growth at a faster pace than revenue.
Cash generation also remained healthy. Operating cash flow came in at $101.7 million, while cash and cash equivalents stood at $74.1 million. At the same time, total liabilities declined 2.2% to $1.08 billion, indicating a slightly leaner balance sheet compared with the prior year.
- Revenue: $1.05 billion, up 7.8%
- Operating profit: $106.7 million, up 29.0%
- Net income: $80.4 million, up 41.4%
- Diluted EPS: $1.44, up 41.2%
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Massmedica S.A. Hedge Fund Activity
We have seen 244 institutional investors add shares of Massmedica S.A. stock to their portfolio, and 210 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,530,616 shares (+inf%) to their portfolio in Q2 2026, for an estimated $182,066,773
- AMERICAN CENTURY COMPANIES INC removed 869,007 shares (-33.3%) from their portfolio in Q2 2026, for an estimated $103,368,382
- MACKENZIE FINANCIAL CORP removed 563,100 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $66,980,745
- POINT72 ASSET MANAGEMENT, L.P. added 490,050 shares (+1184.6%) to their portfolio in Q1 2026, for an estimated $45,216,913
- ALYESKA INVESTMENT GROUP, L.P. removed 375,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $34,601,250
- BALYASNY ASSET MANAGEMENT L.P. added 335,797 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,983,989
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 314,491 shares (-18.4%) from their portfolio in Q1 2026, for an estimated $29,018,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Massmedica S.A. Price Targets
Multiple analysts have issued price targets for $MSM recently. We have seen 2 analysts offer price targets for $MSM in the last 6 months, with a median target of $147.5.
Here are some recent targets:
- Chris Dankert from DA Davidson set a target price of $150.0 on 07/02/2026
- Ken Newman from Keybanc set a target price of $145.0 on 07/02/2026
